CRTC3 promotes melanocyte differentiation and tumorigenesis by integrating cAMP and MAPK/ERK signaling (35), while CRTC2 enhances autophagic flux via PI3K-AKT pathway activation, reducing paclitaxel sensitivity in ovarian cancer cells (36). Here, AKT1 is linked to ovarian carcinoma.